PMID- 20182547
OWN - NLM
STAT- MEDLINE
DCOM- 20100506
LR  - 20211020
IS  - 1687-5443 (Electronic)
IS  - 2090-5904 (Print)
IS  - 1687-5443 (Linking)
VI  - 2009
DP  - 2009
TI  - High-dose glycine treatment of refractory obsessive-compulsive disorder and body 
      dysmorphic disorder in a 5-year period.
PG  - 768398
LID - 10.1155/2009/768398 [doi]
LID - 768398
AB  - This paper describes an individual who was diagnosed with obsessive-compulsive 
      disorder (OCD) and body dysmorphic disorder (BDD) at age 17 when education was 
      discontinued. By age 19, he was housebound without social contacts except for 
      parents. Adequate trials of three selective serotonin reuptake inhibitors, two 
      with atypical neuroleptics, were ineffective. Major exacerbations following ear 
      infections involving Group A beta-hemolytic streptococcus at ages 19 and 20 led 
      to intravenous immune globulin therapy, which was also ineffective. At age 22, 
      another severe exacerbation followed antibiotic treatment for H. pylori. This led 
      to a hypothesis that postulates deficient signal transduction by the 
      N-methyl-D-aspartate receptor (NMDAR). Treatment with glycine, an NMDAR 
      coagonist, over 5 years led to robust reduction of OCD/BDD signs and symptoms 
      except for partial relapses during treatment cessation. Education and social life 
      were resumed and evidence suggests improved cognition. Our findings motivate 
      further study of glycine treatment of OCD and BDD.
FAU - Cleveland, W Louis
AU  - Cleveland WL
AD  - Department of Medicine, St. Luke's-Roosevelt Hospital Center, Columbia 
      University, New York, NY 10019, USA. WLC1@columbia.edu
FAU - DeLaPaz, Robert L
AU  - DeLaPaz RL
FAU - Fawwaz, Rashid A
AU  - Fawwaz RA
FAU - Challop, Roger S
AU  - Challop RS
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100218
PL  - United States
TA  - Neural Plast
JT  - Neural plasticity
JID - 100883417
RN  - 0 (Glycine Agents)
RN  - 0 (Psychotropic Drugs)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Body Dysmorphic Disorders/diagnosis/*drug therapy/metabolism
MH  - Glycine/administration & dosage/*therapeutic use
MH  - Glycine Agents/administration & dosage/therapeutic use
MH  - Humans
MH  - Male
MH  - Models, Neurological
MH  - Obsessive-Compulsive Disorder/diagnosis/*drug therapy/metabolism
MH  - Psychotropic Drugs/administration & dosage/*therapeutic use
MH  - Receptors, N-Methyl-D-Aspartate/metabolism
MH  - Signal Transduction
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC2825652
EDAT- 2010/02/26 06:00
MHDA- 2010/05/07 06:00
PMCR- 2010/02/18
CRDT- 2010/02/26 06:00
PHST- 2009/05/15 00:00 [received]
PHST- 2009/08/12 00:00 [revised]
PHST- 2009/12/04 00:00 [accepted]
PHST- 2010/02/26 06:00 [entrez]
PHST- 2010/02/26 06:00 [pubmed]
PHST- 2010/05/07 06:00 [medline]
PHST- 2010/02/18 00:00 [pmc-release]
AID - 10.1155/2009/768398 [doi]
PST - ppublish
SO  - Neural Plast. 2009;2009:768398. doi: 10.1155/2009/768398. Epub 2010 Feb 18.